Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial Stiffness and Endothelial Function Indexes in Diabetic Patients Treated With Dulaglutide
NCT03824002Phase 4Completed
- Sponsor
- University of Palermo
- Start
- Apr 2017
- Primary completion
- Oct 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Palermo. Primary endpoint: Reactive Hyperemia Index at 9 months. Started Apr 2017; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03824002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824002.